fig6
![Oxidative stress-mediated inflammation promotes the pathogenesis of amyotrophic lateral sclerosis](https://image.oaes.cc/e5ae374c-b040-4105-aaca-ee4d0f551923/5287.fig.6.jpg)
Figure 6. Treg numbers and suppressive function of Tresponder proliferation and disease progression in ALS patients in the Open Label Extension (OLE) of the Phase2A study[46]. The dose escalation was 1X, 2X, and 3X q2 months during the 24 weeks of the Open Label Period. Both Treg numbers and suppressive functions were increased (*P < 0.05) for at least the first 2 weeks. During the OLE the progression rate was slowed in the 6 ALS patients that appeared to have responded to the Treg/IL-2 infusions as monitored by the ALS Functional Rating Scale-Revised; whereas 2 ALS patients were unresponsive to the Treg/IL-2 infusions. ALS: Amyotrophic lateral sclerosis.